HR 1035 116th Congress House Health Administrative remedies Consumer affairs Contracts and agency Health care costs and insurance Health information and medical records Insurance industry and regulation Medical ethics Medicare Prescription drugs Public contracts and procurement Retail and wholesale trades

Prescription Drug Price Transparency Act

Introduced: February 7, 2019 See on congress.gov

Everywhere this bill has been 3 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Feb 7, 2019

Referred to the Subcommittee on Health.

Feb 7, 2019

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Oversight and Reform, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Feb 7, 2019

Introduced in House

Plain-English summary Congressional Research Service

Prescription Drug Price Transparency Act

This bill establishes additional requirements for prescription drug plan sponsors (PDPs) under Medicare and Medicare Advantage, as well as health insurance carriers under the Federal Employees Health Benefits Program, relating to the methodology of payments to pharmacies and the use of pharmacy benefits managers (PBMs).

Specifically, such PDPs and carriers must disclose specified information to pharmacies regarding applicable standards for reimbursement that are based on drug costs, including the sources used to update such standards. Additionally, such PDPs and carriers may not contract with PBMs that require, or that provide an incentive for, plan enrollees to use pharmacies that have a shared ownership interest with the PBM.

What's happening now February 7, 2019

Referred to the Subcommittee on Health.

Committees of jurisdiction 4